Evidence map›Paper›PMID 41509516›Full record

ArticleInternational journal of pharmaceutics: X2026

Ensuring vaccine cold chain integrity: A rapid and low-cost test for identifying heat-exposed sucrose-containing vaccines.

Benediktus Yohan Arman, Andrea Magri, Matteo N Barbaglia, Lawrence Petherbridge, Jennifer Brook, Tehmina Bharucha, Isabelle Legge, John Walsby-Tickle, Michael Deats, Sneha Banerjee and 18 more

Abstract read
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Benediktus Yohan ArmanDepartment of Biochemistry, University of Oxford, OX1 3QU Oxford, UK.
Andrea MagriClinical BioManufacturing Facility, Nuffield Department of Medicine, University of Oxford, OX3 7JT Oxford, UK.
Matteo N BarbagliaDepartment of Biochemistry, University of Oxford, OX1 3QU Oxford, UK.
Lawrence PetherbridgeClinical BioManufacturing Facility, Nuffield Department of Medicine, University of Oxford, OX3 7JT Oxford, UK.
Jennifer BrookDepartment of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, OX3 9DU Oxford, UK.
Tehmina BharuchaDepartment of Biochemistry, University of Oxford, OX1 3QU Oxford, UK.
Isabelle LeggeDepartment of Chemistry, University of Oxford, OX1 3TA Oxford, UK.
John Walsby-TickleDepartment of Chemistry, University of Oxford, OX1 3TA Oxford, UK.
Michael DeatsMedicine Quality Research Group, NDM Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LG, UK.
Sneha BanerjeeCentral Laser Facility, Research Complex at Harwell, STFC Rutherford Appleton Laboratory, UKRI, Harwell Campus, OX11 0QX, UK.
Sara MoscaCentral Laser Facility, Research Complex at Harwell, STFC Rutherford Appleton Laboratory, UKRI, Harwell Campus, OX11 0QX, UK.
Rajender JenaSerum Institute of India Pvt. Ltd., 212/2, Hadapsar, Pune 411028, India.
Dnyanesh S RanadeSerum Institute of India Pvt. Ltd., 212/2, Hadapsar, Pune 411028, India.
Shrikrishna R ChunekarSerum Institute of India Pvt. Ltd., 212/2, Hadapsar, Pune 411028, India.
Kundan D PatilSerum Institute of India Pvt. Ltd., 212/2, Hadapsar, Pune 411028, India.
Sunil GairolaSerum Institute of India Pvt. Ltd., 212/2, Hadapsar, Pune 411028, India.
Hamid A MerchantDepartment of Bioscience, School of Health, Sport and Bioscience, University of East London, Water Lane, London E15 4LZ, UK.
Robert StokesAgilent Technologies LDA UK, Becquerel Avenue, Didcot OX11 0RA, UK.
Rutendo KuwanaRegulation and Safety Unit, Regulation and Prequalification Department, Access to Medicines and Health Products Division, World Health Organization (WHO), Geneva, Switzerland.
Alexandrine MaesRegulation and Safety Unit, Regulation and Prequalification Department, Access to Medicines and Health Products Division, World Health Organization (WHO), Geneva, Switzerland.
Tim JamesDepartment of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, OX3 9DU Oxford, UK.
Catherine GreenClinical BioManufacturing Facility, Nuffield Department of Medicine, University of Oxford, OX3 7JT Oxford, UK.
James McCullaghDepartment of Chemistry, University of Oxford, OX1 3TA Oxford, UK.
Pavel MatousekMedicine Quality Research Group, NDM Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LG, UK.
Céline CailletMedicine Quality Research Group, NDM Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LG, UK.
Paul N NewtonMedicine Quality Research Group, NDM Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LG, UK.
Nicole ZitzmannDepartment of Biochemistry, University of Oxford, OX1 3QU Oxford, UK.
Bevin GangadharanDepartment of Biochemistry, University of Oxford, OX1 3QU Oxford, UK.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Maintaining cold-chain integrity is vital for vaccines to ensure that they remain within the recommended temperature limits during routine storage and transportation. This ensures vaccine stability, efficacy, and avoids degradation. Here, we propose rapid and low-cost tests based on simple glucose assays to detect heat-exposed degraded sucrose-containing vaccines through sucrose's inherent gradual conversion to glucose when exposed to elevated temperatures. Bioluminescent and colorimetric assays and a clinical biochemical analyser for urine samples could successfully determine effects of heat exposure on vaccines by detecting a significant increase in glucose levels. We show that this increase in glucose also correlates with the loss of vaccine potency. When vaccines were incubated at 37 and 45 °C, the bioluminescent assay was able to detect an increase in glucose levels from 12 h of heat exposure. The biochemical analyser could successfully detect increased glucose levels in a COVID-19 vaccine which had been exposed to 37 and 45 °C. Most importantly, the colorimetric assay has the advantage of producing a colour change visually upon simply mixing the vaccine with a reagent without the need for a plate reader or any other sophisticated devices. To our knowledge, this is the first simple, rapid and device-free test of its kind to detect heat-exposed substandard vaccines, making it a potential test for deploying at key points in the supply chain in warm and hot countries to check the integrity of vaccine cold-chain. Although this test does not replace the more definitive lot release assays such as potency assays, it could initially be used as a rapid and low-cost test to identify substandard sucrose-containing vaccines within supply chains, in support of WHO's Prevent, Detect, and Respond strategy.

Indexed as

Cold chainDegradationGlucosePotencySubstandardSucroseSupply chainVaccine

Identifiers

PMID41509516
PMCPMC12774715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.